P01.03 Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC von Jänne, P., Rajagopalan, R., Pudussery, G., Shrestha, P., Chen, S., Hodge, R., Qiu, Y., Yu, C.

Volltext

P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer von Raghav, K., Yoshino, T., Taniguchi, H., Tejpar, S., Vogel, A., Wainberg, Z., Yamaguchi, K., Fakih, M., Pedersen, K., Bando, K., Kawakami, H., Beck, J., Kanai, M., Liu, Y., Mekan, S., Pudussery, G., Qiu, Y., Kopetz, S.

Volltext

65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously unt... von Peters, S., Tan, D.S.W., Gerber, D.E., Urbanic, J., Ramalingam, S.S., Yu, J., Xing, L., Rittmeyer, A., Ciuleanu, T-E., Menezes, J., Kim, H.R., Rojas, C.I., Syrigos, K., Hayashi, H., Haridass, A., Bordenave, S., Nathani, R., Pudussery, G., Yang, L., De Ruysscher, D.

Volltext

Valence rearrangement of hetero systems. The 4-isoxazolines von Baldwin, J. E, Pudussery, R. G, Qureshi, A. K, Sklarz, B

Volltext

The preparation of 2,2,2-trideuterioacetaldehyde von Baldwin, J. E., Pudussery, R. G.

Volltext

Direct alkylation of nitroso-compounds to nitrones von Baldwin, J. E., Pudussery, R. G., Sklarz, B., Sultan, M. K.

Volltext